Search

Background Computed tomography perfusion (CTP) predictions of infarct core play an important role in the determination of treatment eligibility in large‐vessel occlusion acute ischemic stroke. Prior studies have demonstrated that blood glucose can affect cerebral blood flow. Here, we examine the influence of acute and chronic hyperglycemia on CTP estimations of infarct core. Methods From our prospectively collected multicenter observational cohort, we identified patients with large‐vessel occlusion acute ischemic stroke who underwent CTP with RAPID (IschemaView, Stanford, CA) postprocessing, followed by endovascular therapy with substantial reperfusion (Thrombolysis in Cerebral Infarction 2b–3) within 90 minutes, and final infarct volume determination by magnetic resonance imaging 48 to 72 hours posttreatment. Core volume overestimations and underestimations were defined as a difference of at least 20 mL between CTP‐RAPID predicted infarct core and Diffusion Weighted Imaging (DWI) final infarct volume. Primary outcome was the association of presentation glucose and hemoglobin A1c (HgbA1c) with underestimation of core volume and was measured using multivariable logistic regression adjusted for comorbidities and presentation characteristics. Secondary outcomes included frequency of overestimation of infarct core. Results Among 256 patients meeting inclusion criteria, median age was 67 (interquartile range [IQR], 57–77) years, 51.6% were women, and 132 (51.6%) and 93 (36.3%) had elevated presentation glucose and elevated HgbA1c, respectively. Median CTP‐predicted core was 6 mL (IQR, 0–30 mL), median DWI final infarct volume was 14 mL (IQR, 6‐43 mL), and median difference was 12 mL (IQR, 5–35 mL). Twenty‐eight (10.9%) patients had infarct core overestimation and 68 (26.6%) had underestimation. Compared with those with no underestimation, patients with underestimation had elevated blood glucose (median, 119 [IQR, 103–155] versus 138 [IQR, 117–195] mg/dL; P = 0.002) and HgbA1c (median, 5.80% [IQR, 5.40–6.40] versus 6.40% [IQR, 5.50–7.90]; P = 0.009). In multivariable analysis, underestimation was independently associated with elevated glucose (adjusted odds ratio [OR], 2.10; P = 0.038) and HgbA1c (adjusted OR, 2.37; P = 0.012). Overestimation was associated with lower presentation blood glucose (median, 109 [IQR, 99–132] in overestimation versus 127 [IQR, 107–172] mg/dL in no overestimation; P = 0.003) and HgbA1c (5.6%[IQR 5.1–6.2] in overestimation versus 5.90%[IQR, 5.50–6.70] in no overestimation; P = 0.012). Conclusions Acute and chronic hyperglycemia were strongly associated with CTP underestimation in patients with large‐vessel occlusion acute ischemic stroke undergoing endovascular therapy. Glycemic state should be considered when interpreting CTP findings in patients with large‐vessel occlusion acute ischemic stroke.

Background Because of the variability in patient responses to clopidogrel and to reduce the risk of thromboembolic complications, adjusting the antiplatelet regimen based on platelet function testing has become a widespread practice in neurointervention. We aimed to explore current patterns related to this practice. Methods We conducted a survey targeting neurointerventionalists, comprising multiple‐choice questions and opportunities for free‐text responses when necessary. The survey was distributed via a professional society distribution list (the Society of Vascular and Interventional Neurology) and 2 consortium emailing lists (WovenEndoBridge and Neurointerventional Research Consortia). The data obtained from the responses were analyzed using descriptive statistics. Results A total of 133 neurointerventionalists, representing 79 institutions within 27 countries, responded to the survey. A total of 62% of respondents tested for clopidogrel resistance before any neurovascular stent placements. A total of 80% used VerifyNow point‐of‐care P2Y12 assay; other assays included multiplate analyzer, platelet function analyzer, and CYP2C19 genotype assay. Respondents reported 25 different therapeutic thresholds, with the P2Y12 reaction unit range between 60 and 180 most commonly used (16.4%). A total of 61% reported they would switch to ticagrelor in the case of persistent resistance. On the other hand, when patients are supratherapeutic, 48% did not make any changes, whereas 42% reduced clopidogrel dose. Finally, 93% opined that a well‐established protocol for management of clopidogrel resistance was needed. Conclusions Neurointerventional practice patterns around clopidogrel resistance remain heterogeneous. Our results underscore the need for evidence‐based guidance on the management of clopidogrel resistance in neurointervention.